[
Abbara A, Clarke SA, Nesbitt A, Ali S, Comninos AN, Hatfield E, Martin NM, Sam AH, Meeran K, Dhillo WS. Interpretation of serum gonadotropin levels in hyperprolactinaemia. Neuroendocrinology 107, 2, 105–113, 2018.10.1159/00048926429660734
]Search in Google Scholar
[
Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am 4, 89–97, 2015.10.1016/j.ecl.2014.10.00725732645
]Search in Google Scholar
[
Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 846, 1–35, 2015.10.1007/978-3-319-12114-7_125472532
]Search in Google Scholar
[
Bernard V, Young J, Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 15, 356–365, 2019.10.1038/s41574-019-0194-630899100
]Search in Google Scholar
[
Bima C, Chiloiro S, Giampietro A, Gessi M, Mattogno PP, Lauretti L, Anile C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. Galectin-3 and estrogen receptor alpha as prognostic markers in prolactinoma: preliminary results from a pilot study. Front Endocrinol 12, 684055, 2021.10.3389/fendo.2021.684055831224534322092
]Search in Google Scholar
[
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65, 265–273, 2006.10.1111/j.1365-2265.2006.02562.x16886971
]Search in Google Scholar
[
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33, 101290, 2019.10.1016/j.beem.2019.10129031326373
]Search in Google Scholar
[
Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11, 787–800, 2002.10.1517/13543784.11.6.78712036422
]Search in Google Scholar
[
Colao A, di Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148, 325–331, 2003.10.1530/eje.0.148032512611613
]Search in Google Scholar
[
Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82, 2102–2107, 1997.10.1210/jc.82.7.2102
]Search in Google Scholar
[
Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16, 545–553, 2013.10.1007/s11102-012-0454-023239049
]Search in Google Scholar
[
Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18, 745–751, 2015.10.1007/s11102-014-0617-225500765
]Search in Google Scholar
[
Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94, 2729–2734, 2009.10.1210/jc.2009-017719491225
]Search in Google Scholar
[
Lu C, Liu Y, Lu Z, Huan C. Ki-67 and clinical correlations in patients with resistant prolactinomas. Ann Clin Lab Sci 50, 199–204, 2020.
]Search in Google Scholar
[
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 273–288, 2011.10.1210/jc.2010-169221296991
]Search in Google Scholar
[
Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51, 205–210, 2016.10.1007/s12020-015-0727-226336835
]Search in Google Scholar
[
Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord 26, 21, 81, 2021.
]Search in Google Scholar
[
Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A, Mantovani G. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest 39, 1377–1382, 2016.10.1007/s40618-016-0483-z27245604
]Search in Google Scholar
[
Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22, 1785–1791, 2015.10.1016/j.jocn.2015.06.00126277642
]Search in Google Scholar
[
Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 20, 464–70, 2017.10.1007/s11102-017-0806-x28523537
]Search in Google Scholar
